Article Details

FDA approval sets stage for a showdown between Alexion and Apellis

Retrieved on: 2021-05-17 15:45:00

Tags for this article:

Click the tags to see associated articles and topics

FDA approval sets stage for a showdown between Alexion and Apellis. View article details on hiswai:

Excerpt

Alexion recorded just over $5.1 billion in net sales from those two drugs last year, with Soliris accounting for about 80% of the total. Dive Insight: Alexion ...

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up